Takeda Pharmaceutical Co., Ltd

PharmaVitae Profile

Product Code DAT21538
Publication Date October 2010
Publisher Datamonitor
Product Type Report
Pages 128
ISBN Number not applicable
Change currency
PDF £3,605.00 €4,341 $5,700 BUY >
PRINT £3,670 €4,420 $5,803 BUY >
Order by fax
Ask a question about this product > Receive product alerts > Call now +44 20 7060 7474

Takeda Pharmaceutical Co., Ltd

PharmaVitae Profile

This analysis examines the historical and forecast performance for Takeda in the prescription pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs.

Features and benefits:

  • Gain insight into Takeda's strategic outlook across the next 6 years
  • Analyze company sales forecasts by product, therapy area, lifecycle stage, geography, molecule type and source.

Highlights:

  • Strategic insight into the prospects for Takeda over the next six years. Picking out key strengths, weaknesses, opportunities and threats and evaluating the company's prescription pharmaceuticals outlook using a variety of cuts of the historical and forecast sales.

Your key questions answered:

  • Benchmark Takeda's performance against key rivals in the prescription pharmaceutical sector
  • Discover if Takeda will overcome generic competition facing its biggest selling medications
  • Investigate the diverse strategies being employed by Japan's oldest and largest pharmaceutical player

Contents

  • About Datamonitor Healthcare
    • About the PharmaVitae team
  • Chapter 1 About this profile
    • PharmaVitae Explorer database
  • Chapter structure
    • Data sourcing
  • Chapter 2 Executive Summary
    • Key findings
    • Prescription pharmaceutical sales and growth rate performance, 2003-15
    • Financial performance, 2003-15
    • Takeda: PharmaVitae forecasts at a glance
    • Strategic insight
    • SWOT analysis
  • Chapter 3 Quarterly news update
    • Latest prescription pharma product news
    • Latest corporate news
    • Future product milestones
  • Chapter 4 Company introduction
    • Key findings
    • Background
    • Key corporate developments
    • M&A history
  • Chapter 5 Company sales
    • Key findings
    • Prescription pharmaceutical sales and growth rate analysis, 2003-15
    • Product analysis
    • Therapy area analysis
    • Geographic analysis
    • Launch/core/expiry analysis
    • Molecule type analysis
    • Externalization analysis
  • Chapter 6 Company financials
    • Key findings
    • Reconciliation between PharmaVitae-formatted prescription pharma sales and company-reported total sales, 2003-09
    • Operating costs and profit analysis
  • Chapter 7 Key products
    • Overview
  • Chapter 8 Appendix
    • References
    • Abbreviations
    • Exchange rates
    • About Datamonitor
    • Datamonitor consulting
    • Disclaimer
  • Table Of Tables
    • Table 1: Takeda - PharmaVitae forecasts at a glance
    • Table 2: Takeda future product milestones, 2010-12
    • Table 3: Takeda product portfolio overview ($m), 2003-09
    • Table 4: Takeda product portfolio overview ($m), 2009-15
    • Table 5: Takeda prescription pharmaceutical sales by therapy area ($m), 2009-15
    • Table 6: Takeda prescription pharmaceutical sales by geographic region ($m), 2009-15
    • Table 7: Takeda launch portfolio overview ($m), 2009-15
    • Table 8: Takeda core portfolio overview ($m), 2009-15
    • Table 9: Takeda expiry portfolio overview ($m), 2009-15
    • Table 10: Takeda prescription pharmaceutical sales by molecule type ($m), 2009-15
    • Table 11: Takeda prescription pharmaceutical sales by source ($m), 2009-15
    • Table 12: Total Takeda sales by business unit ($m), 2003-09
    • Table 13: Takeda operating revenue/cost analysis ($m), 2003-09
    • Table 14: Takeda operating cost ratio analysis (% of total revenues), 2003-09
    • Table 15: Takeda operating cost ratio analysis (% of total revenues), 2009-15
    • Table 16: Takeda operating revenue/cost analysis ($m), 2009-15
    • Table 17: Takeda Key products overview
    • Table 18: Dexilant: overview
    • Table 19: Dexilant: sales forecast ($m), 2009-15
    • Table 20: Blopress: overview
    • Table 21: Blopress comp: overview
    • Table 22: Blopress: sales forecast ($m), 2009-15
    • Table 23: Blopress comp: sales forecast ($m), 2009-15
    • Table 24: Actos: overview
    • Table 25: ACTOplus met: overview
    • Table 26: Actos: sales forecast ($m), 2009-15
    • Table 27: ACTOplus met: sales forecast ($m), 2009-15
    • Table 28: Lupron Depot: overview
    • Table 29: Lupron Depot: sales forecast ($m), 2009-15
    • Table 30: Velcade: overview
    • Table 31: Velcade: sales forecast ($m), 2009-15
    • Table 32: Alogliptin: overview
    • Table 33: Alogliptin/ACTOS combo: overview
    • Table 34: Alogliptin: sales forecast ($m), 2009-15
    • Table 35: Alogliptin/ACTOS combo: sales forecast ($m), 2009-15
    • Table 36: Enbrel: overview
    • Table 37: Enbrel: sales forecast ($m), 2009-15
    • Table 38: Amitiza: overview
    • Table 39: Amitiza: sales forecast ($m), 2009-15
    • Table 40: Exchange rates, 2010
  • Table Of Figures
    • Figure 1: The PharmaVitae Explorer
    • Figure 2: Takeda prescription pharmaceutical performance, sales ($m) and growth rate (%), 2003-15
    • Figure 3: Takeda's financial performance ($m), 2003-15
    • Figure 4: Major expiry product sales ($m), 2009-15
    • Figure 5: Oncology investment drives long-term therapeutic strategy
    • Figure 6: Lifecycle management of gastroenterology portfolio, sales ($m), 2009-15
    • Figure 7: Lifecycle management of antidiabetic portfolio, sales ($m), 2009-15
    • Figure 8: Takeda SWOT analysis
    • Figure 9: Takeda prescription pharmaceutical performance, sales ($m) and growth rate (%), 2003-15
    • Figure 10: Takeda Key product sales ($m), 2003-15
    • Figure 11: Takeda key sales growth drivers and resistors ($m), 2003-09
    • Figure 12: Takeda key sales growth drivers and resistors ($m), 2009-15
    • Figure 13: Takeda prescription pharmaceutical sales by therapy area ($m), 2003-15
    • Figure 14: Takeda prescription pharmaceutical sales by geographic region ($m), 2003-15
    • Figure 15: Takeda launch/core/expiry configuration ($m), 2009-15
    • Figure 16: Takeda prescription pharmaceutical sales by molecule type ($m), 2003-15
    • Figure 17: Takeda prescription pharmaceutical sales by source ($m), 2003-15
    • Figure 18: Takeda operating revenue/cost analysis ($m), 2003-15
    • Figure 19: Dexilant sales by geography and analyst consensus ($m), 2003-15
    • Figure 20: Blopress sales by geography and analyst consensus ($m), 2003-15
    • Figure 21: Blopress comp sales by geography and analyst consensus ($m), 2003-15
    • Figure 22: Actos sales by geography and analyst consensus ($m), 2003-15
    • Figure 23: ACTOplus met sales by geography and analyst consensus ($m), 2003-15
    • Figure 24: Lupron Depot sales by geography and analyst consensus ($m), 2003-15
    • Figure 25: Velcade sales by geography and analyst consensus ($m), 2003-15
    • Figure 26: Alogliptin sales by geography and analyst consensus ($m), 2003-15
    • Figure 27: Alogliptin/ACTOS combo sales by geography and analyst consensus ($m), 2003-15
    • Figure 28: Enbrel sales by geography and analyst consensus ($m), 2003-15
    • Figure 29: Amitiza sales by geography and analyst consensus ($m), 2003-15